Vir Biotechnology to Participate in Upcoming Investor Conferences

About this update from Vir Biotechnology, Inc.

SAN FRANCISCO --(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference : Marianne De Backer , M.Sc ., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Monday, March 2, 2026 , at 3:10 p.m. ET / 12:10 p.m. PT in Boston, Massachusetts . Leerink Partners Global Healthcare Conference : Marianne De Backer , M.Sc ., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 10, 2026 , at 1:40 p.m. ET / 10:40 a.m. PT in Miami, Florida . Barclays 28th Annual Global Healthcare Conference : Members of management will be available for one-on-one meetings on Thursday, March 12, 2026 , in Miami, Florida . Live webcasts of the fireside chats will be available at https://investors.vir.bio and will be archived for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc. , a Sanofi company. View source version on businesswire.com : https://www.businesswire.com/news/home/20260226768056/en/ Media Contact Caren Scannell Director, Communications [email protected] Investor Contact Kiki Patel , PharmD Head of Investor Relations [email protected] Source: Vir Biotechnology, Inc.

View stock analysis, news, and events for Vir Biotechnology, Inc.